Large bio­phar­ma com­pa­nies cull about 40 im­muno-on­col­o­gy pro­grams over the last two quar­ters

Clin­i­cal tri­al fail­ures, pa­tient en­roll­ment strug­gles, new pri­or­i­ties and a trans­formed FDA are just a few of the rea­sons why some of the top bio­phar­ma com­pa­nies de­cid­ed to cut about 40 dif­fer­ent im­muno-on­col­o­gy de­vel­op­ment pro­grams over the last two quar­ters, an SVB Se­cu­ri­ties analy­sis shows — con­firm­ing more than a half dozen End­points News ar­ti­cles.

As­traZeneca, Bris­tol My­ers Squibb, Roche, Janssen, Bay­er, Pfiz­er, Gilead, Ab­b­Vie and Mer­ck KGaA all cut 21 dif­fer­ent IO pro­grams linked to a va­ri­ety of new and fol­low-on in­di­ca­tions, ac­cord­ing to SVB Se­cu­ri­ties’ tal­ly for Q4.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.